European Medicines Agency's Committee for Medicinal Products for Human Use starts rolling review of molnupiravir for treatment of COVID-19 in adults, EMA

Decision to start rolling review of this oral antiviral medicine is based on preliminary results from lab and clinical studies suggesting it may reduce ability of SARS CoV 2 to multiply in the body, thereby preventing hospitalisation or death in patients with COVID-19.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news

Related Links:

Lithium, a mood stabilizer used in the treatment of bipolar disorder is known for its anti-inflammatory properties with the discussion of its potential use in COVID-19 infection. The SARS-CoV-2 virus causing COVID-19 infection is known to enter the target cells through angiotensin converting enzyme-2 receptors present in abundance in the lung and renal tissue. Recent research supports the evidence for direct renal injury by viral proteins. Here we report two patients with bipolar disorder presenting with lithium toxicity in the presence of COVID-19 infection. Two patients with bipolar disorder, maintaining remission on lit...
Source: International Clinical Psychopharmacology - Category: Psychiatry Tags: Case Reports Source Type: research
Giving solid-organ-transplant recipients a fourth dose of mRNA COVID-19 vaccine may lead to only a slight improvement in SARS-CoV-2 antibody concentrations for some patients, according to a study from France.Reuters Health Information
Source: Medscape Transplantation Headlines - Category: Transplant Surgery Tags: Infectious Diseases News Source Type: news
Conclusion: Immune assessment resulted in favorable anakinra responses among critically ill patients with COVID-19 and features of MALS.J Innate Immun
Source: Journal of Innate Immunity - Category: Allergy & Immunology Source Type: research
Latest updates on SARS-CoV-2 variants detected in the UK. 1 December 2021Added breakdown of cases by local authority to latest update. 30 November 2021Added latest update.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news
Comb Chem High Throughput Screen. 2021 Nov 30. doi: 10.2174/1386207325666211130140923. Online ahead of print.ABSTRACTInfection by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) provokes acute inflammation due to extensive replication of the virus in the epithelial cells of the upper and lower respiratory system. The mammalian target of rapamycin (mTOR) is a l signalling protein with critical functions in cell growth, metabolism, and proliferation. It is known for its regulatory functions in protein synthesis and angiogenesis cascades. The structure of mTOR consists of two distinct complexes (mTORC1 and mT...
Source: Combinatorial Chemistry and High Throughput Screening - Category: Chemistry Authors: Source Type: research
GISAID hosts a vast, open database of genomic sequences of SARS-CoV-2 coronavirus samples, and medical laboratory scientists in countries across the globe are contributing Clinical laboratories around the world have been contributing to the global scientific community’s database of knowledge about SARS-CoV-2, the coronavirus that caused the COVID-19 pandemic, and its variants, through an ingenious […] The post More Countries Are Now Capable of Genome Sequencing and Contributing to Global COVID-19 GISAID Database than Ever Before appeared first on Dark Daily.
Source: Dark Daily - Category: Laboratory Medicine Authors: Tags: Digital Pathology International Laboratory News Laboratory Instruments & Laboratory Equipment Laboratory Pathology Laboratory Resources Laboratory Testing Molecular Diagnostics, Genetic Testing, Whole Gene Sequencing Precision Medicine ACE Source Type: news
In this study, we characterized the haplotype and sub-haplotype diversity of SARS-CoV-2 global variants in January-March and the areas with low and high COVID19 vaccination rates in May 2021 by analyzing viral proteome of complete genome sequences published. Phylogenetic tree analysis of the proteomes of SARS-CoV-2 variants with Neighbor-Joining and Maximum Parsimony methods indicated that haplotype 2 variant with nsp12 P323L and Spike D614G was dominant (98.81%), including new sub-haplotypes 2A_1 to 2A_3, 2B_1 to 2B_3, and 2C_1 to 2C_2 emerged post-one-year COVID-19 outbreak. In addition, the profiling of sub-haplotypes i...
Source: Infection, Genetics and Evolution - Category: Genetics & Stem Cells Authors: Source Type: research
CONCLUSIONS: Bronchoscopy in patients with COVID-19 results in a significant change in patient management. Transmission of SARS-CoV-2 seems to be low with consistent use of appropriate personal protective equipment by health-care workers. Therefore, bronchoscopic evaluation should be considered for all diagnostic and therapeutic indications in this patient population.PMID:34848547 | DOI:10.4187/respcare.09405
Source: Respiratory Care - Category: Respiratory Medicine Authors: Source Type: research
AbstractTwo mRNA coronavirus disease 2019 (COVID-19) vaccines, BNT162b2 and mRNA-1273, are effective to prevent infection of SARS-CoV-2 and to prevent developing severe COVID-19 in the general population. Although BNT162b2 elicits CD4+ and CD8+ T-cell responses, mRNA-1273 induces poor CD8+ responses. Therefore, the effect of mRNA-1273 vaccine might be weak in patients treated with anti-CD20 monoclonal antibodies, showing a marked decrease of anti-SARS-CoV-2 antibody production after COVID-19 vaccination. We discuss a selection of mRNA vaccines based on their different CD8+ T-cell functions in multiple sclerosis patients wi...
Source: Clinical and Experimental Neuroimmunology - Category: Neurology Authors: Tags: COMMENTARY Source Type: research
This study, which examined the impact of SARS-Cov-2 infection and COVID-19 vaccination on ovarian function, revealed no evidence for compromised follicular function or fertility.Human Reproduction
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health Journal Article Source Type: news
More News: COVID-19 | European Medicines Agency (EMA) | Health | SARS | Study